Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast cancer prevention: How nurse practitioners and physician assistants can help

2.

FDA Expands Durvalumab Label to Operable Lung Cancer

3.

ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death

4.

Mapping lifelong chronic health risks for childhood cancer survivors

5.

Adding Daratumumab to VRd Boosts MRD Negativity in Transplant-Ineligible Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot